Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Key Points

• Zurcher Kantonalbank sold 1,553 shares of Charles River Laboratories, reducing its stake by 14.0%, now holding 9,521 shares valued at approximately $1.43 million.
• Several hedge funds have recently increased their positions in Charles River Laboratories, with Assenagon Asset Management seeing a 1,721.1% growth in shares.
• Analysts' ratings vary, with a consensus rating of "Hold" and a target price of $174.54, while Citigroup upgraded its rating from "neutral" to "buy" with a new target of $200.00.

Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 14.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,521 shares of the medical research company's stock after selling 1,553 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Charles River Laboratories International were worth $1,433,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of CRL. Rothschild Investment LLC grew its holdings in Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock valued at $26,000 after purchasing an additional 144 shares during the last quarter. HM Payson & Co. acquired a new stake in shares of Charles River Laboratories International during the 1st quarter worth $31,000. Optiver Holding B.V. purchased a new stake in Charles River Laboratories International during the fourth quarter valued at about $37,000. GeoWealth Management LLC raised its holdings in shares of Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares during the period. Finally, Huntington National Bank grew its holdings in shares of Charles River Laboratories International by 120.6% during the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after purchasing an additional 164 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Down 0.1%

Shares of NYSE CRL traded down $0.15 during trading hours on Thursday, hitting $150.19. The company's stock had a trading volume of 699,474 shares, compared to its average volume of 1,287,047. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $230.02. The business has a 50-day simple moving average of $155.03 and a 200-day simple moving average of $149.60. The stock has a market cap of $7.38 billion, a price-to-earnings ratio of -230.29, a P/E/G ratio of 5.67 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.62. The business had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The firm's quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.80 EPS. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Evercore ISI lifted their price target on shares of Charles River Laboratories International from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. Robert W. Baird lifted their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Finally, Barclays boosted their price target on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the company an "equal weight" rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus target price of $175.31.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the sale, the executive vice president directly owned 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).